Orforglipron
Foundayo · LY3502970 · Oral GLP-1 receptor agonist (non-peptide)
Reviewed by the BestHealingPeptides Editorial Team ·
On this page
What is orforglipron, and is it licensed in the UK?
Orforglipron is an oral, non-peptide GLP-1 receptor agonist taken as a once-daily tablet. In the UK the MHRA authorised it as Foundayo on 10 August 2026, a prescription only medicine for weight management in adults and for insufficiently controlled type 2 diabetes in adults.
Sources: Foundayo SmPC (emc); MHRA announcement, 10 August 2026
Sourced facts at a glance
- Mechanism and half-life: An oral high-affinity nonpeptide agonist of the human GLP-1 receptor. Elimination half-life approximately 29 to 49 hours, maximum concentration 4 to 8 hours after a dose, steady state after approximately 1 week of once-daily dosing. (Foundayo SmPC (emc))
- UK brand, status and licensed indications: Foundayo film-coated tablets (0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg) are a prescription only medicine. Indicated for weight management in adults with a BMI of 30 kg/m2 or more, or 27 to under 30 kg/m2 with at least one weight-related comorbidity, and for insufficiently controlled type 2 diabetes mellitus in adults as an adjunct to diet and exercise. (Foundayo SmPC (emc); MHRA announcement, 10 August 2026)
- UK authorisation date and NHS status: Authorised by the MHRA on 10 August 2026 (marketing authorisation holder Eli Lilly Nederland B.V.). The MHRA states it is not currently available via the NHS and that decisions on NHS use will follow established processes, including an evaluation by NICE. (MHRA announcement, 10 August 2026; Foundayo SmPC (emc))
- Licensed dosing: Start 0.8 mg once daily; after at least 30 days increase to 2.5 mg, then 5.5 mg, and if needed to 9 mg, 14.5 mg or 17.2 mg, with at least 30 days on each dose. Maximum 17.2 mg once daily. Taken at any time of day without food or water restriction. (Foundayo SmPC (emc))
- US and EU status: The FDA approved Foundayo on 1 April 2026 (NDA 220934) for adults with obesity or overweight with weight-related comorbidity. The CHMP adopted a positive opinion on 15 October 2026; the EMA page records an opinion, and a European Commission decision had not been confirmed when this page was last updated. (FDA Novel Drug Approvals 2026; DailyMed Foundayo label; EMA Foundayo page)
- Head-to-head trial against oral semaglutide (ACHIEVE-3): In 1698 adults with type 2 diabetes inadequately controlled with metformin, HbA1c change at 52 weeks was -1.71% with orforglipron 12 mg and -1.91% with 36 mg versus -1.23% with oral semaglutide 7 mg and -1.47% with 14 mg; both orforglipron doses were superior to both semaglutide doses. (Rosenstock et al., Lancet 2026 (PMID 41765029))
- Hepatic safety (pooled Phase 3 analysis): In a pooled analysis of seven Phase 3 trials (11,220 participants, 6,920 on orforglipron), orforglipron treatment was not associated with drug-induced liver injury. (Wharton et al., Diabetes Obes Metab 2026 (PMID 42338042))
An oral, non-peptide GLP-1 receptor agonist taken as a once-daily tablet. Orforglipron (Foundayo, Eli Lilly) was approved by the US FDA on 1 April 2026 for adults with obesity or overweight, and was authorised by the MHRA in the UK on 10 August 2026 for weight management and for insufficiently controlled type 2 diabetes in adults. In the UK it is a prescription only medicine supplied as film-coated tablets in six strengths from 0.8 mg to 17.2 mg, taken at any time of day without food or water restriction (UK SmPC section 4.2). The CHMP adopted a positive opinion for the EU on 15 October 2026; a European Commission decision had not been confirmed when this page was last updated. The gov.uk announcement states that it is not currently available via the NHS.
Mechanism of action
Orforglipron (Eli Lilly development code LY3502970) is described in section 5.1 of the UK SmPC as an oral high-affinity nonpeptide GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor. It is a small molecule rather than a peptide: PubChem gives its molecular formula as C48H48F2N10O5 and its molecular weight as 883.0. The UK SmPC states that each film-coated tablet contains orforglipron calcium.
On appetite and body weight, the SmPC notes that GLP-1 receptors exist in brain regions that regulate appetite, and that in animal studies orforglipron distributed to and activated neurons in those regions and decreased food intake. It states that orforglipron reduces body weight, with greater fat mass loss than lean mass loss, and reduces visceral adipose tissue; it decreases food intake, an effect likely mediated by decreased appetite.
On glycaemic control, the SmPC states that orforglipron lowers fasting, pre- and postprandial glucose through several mechanisms, including increased glucose-dependent insulin secretion, decreased fasting glucagon and increased insulin sensitivity. It delays gastric emptying; the delay is largest after the first dose and diminishes over time. In pooled placebo-controlled Phase 3 studies, treatment across orforglipron doses resulted in a mean decrease in systolic and diastolic blood pressure.
Pharmacokinetics (SmPC section 5.2). Orforglipron is eliminated by metabolism: it is metabolised primarily via hepatic CYP3A4 (and, in vitro, CYP2J2), and is a substrate of P-gp, OATP1B1 and OATP1B3. The primary excretion route of its metabolites is faeces, and less than 1% of an oral dose is excreted in urine. The geometric mean absolute bioavailability was 77% after a 1 mg capsule dose and decreased with increasing capsule dose. No clinically relevant food effect was observed, and orforglipron can be taken with or without food.
Tablets and trial capsules. Clinical studies were conducted with a hard capsule form (1, 3, 6, 12, 24 and 36 mg). The licensed film-coated tablets (0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg) are not substitutable with the capsules on a mg-per-mg basis; SmPC Table 2 lists equal-effect pairs of 0.8 mg tablet to 1 mg capsule, 2.5 to 3, 5.5 to 6, 9 to 12, 14.5 to 24 and 17.2 to 36 mg. This is why the Phase 3 trial doses (for example 6, 12 and 36 mg in ATTAIN-1) differ from the licensed tablet strengths.
Origin. Lilly's press release of 1 April 2026 states that orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018.
In ACHIEVE-3 (Lancet 2026, PMID 41765029; open-label, 52 weeks, 1698 adults with type 2 diabetes inadequately controlled with metformin), orforglipron 12 mg and 36 mg capsules were non-inferior and superior to oral semaglutide 7 mg and 14 mg for HbA1c change (-1.71% and -1.91% versus -1.23% and -1.47%), with higher rates of gastrointestinal events and discontinuations due to adverse events. In ATTAIN-1 (NEJM 2025, PMID 40960239) the 36 mg capsule produced a mean body-weight change of -11.2% versus -2.1% with placebo at 72 weeks (treatment-regimen estimand). In ACHIEVE-4 (Lancet 2026, PMID 42815506) orforglipron was non-inferior to insulin glargine for major adverse cardiovascular events (hazard ratio 0.84; 95% CI 0.59 to 1.20).
— Notable finding
Development history
Origin. According to Lilly, orforglipron (development code LY3502970) was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. The marketing authorisation holder for Foundayo in the UK is Eli Lilly Nederland B.V. (UK SmPC on the emc).
Phase 2. The Phase 2 obesity trial (Wharton et al., NEJM 2023, PMID 37351564) randomised 272 adults without diabetes to orforglipron 12, 24, 36 or 45 mg or placebo for 36 weeks; mean weight change at week 36 ranged from -9.4% to -14.7% with orforglipron versus -2.3% with placebo. The Phase 2 type 2 diabetes trial (Frias et al., Lancet 2023, PMID 37369232) randomised 383 adults for 26 weeks; mean HbA1c change was up to -2.10% with orforglipron versus -0.43% with placebo, and mean body-weight change was up to -10.1 kg.
Phase 3. The ATTAIN trials in obesity and overweight and the ACHIEVE trials in type 2 diabetes have been published. ATTAIN-1 (NEJM 2025, PMID 40960239) and ATTAIN-2 (Lancet 2025, PMID 41275875) reported weight outcomes at 72 weeks. ACHIEVE-1 (NEJM 2025, PMID 40544435), ACHIEVE-2 (Lancet 2026, PMID 42259339), ACHIEVE-3 (Lancet 2026, PMID 41765029) and ACHIEVE-5 (JAMA 2026, PMID 42251769) reported HbA1c outcomes against placebo, dapagliflozin, oral semaglutide and placebo on a background of insulin glargine respectively. The cardiovascular safety trial is ACHIEVE-4 (Lancet 2026, PMID 42815506), in which orforglipron was non-inferior to insulin glargine for a four-component major adverse cardiovascular event outcome (hazard ratio 0.84; 95% CI 0.59 to 1.20). ATTAIN-MAINTAIN (Nature Medicine 2026, PMID 42120723) studied maintenance of weight reduction in people switched from tirzepatide or semaglutide. A pooled hepatic safety analysis of seven Phase 3 trials (Diabetes Obes Metab 2026, PMID 42338042) concluded that orforglipron treatment was not associated with drug-induced liver injury.
Regulatory timeline. The FDA approved Foundayo on 1 April 2026 (NDA 220934; Drugs@FDA lists the original approval as 2026-04-01, classified as a new molecular entity) for adults with obesity or overweight with weight-related comorbidity; the US label has no type 2 diabetes indication, and Lilly's second-quarter 2026 results list a US type 2 diabetes submission under regulatory progress. The MHRA authorised Foundayo on 10 August 2026 for weight management and type 2 diabetes (gov.uk press release; UK SmPC section 9 gives 10 August 2026 as the date of first authorisation), which the MHRA described as making the UK the first country in Europe to approve this tablet for these uses. On 15 October 2026 the EMA's CHMP adopted a positive opinion recommending a marketing authorisation for Foundayo for type 2 diabetes and weight management; the EMA page states that the SmPC will be published after the marketing authorisation has been granted by the European Commission, and a Commission decision had not been confirmed when this page was last updated.
Licensed dose regimens
The regimens below are summarised from the UK Summaries of Product Characteristics. They are not a dosing recommendation; follow your prescriber.
| Indication | Route | Regimen | Note |
|---|---|---|---|
| Weight management in adults (Foundayo, MHRA-licensed) | Oral, once daily | Start 0.8 mg once daily. After at least 30 days increase to 2.5 mg once daily; after at least 30 days on the current dose increase to 5.5 mg; the dose may then be increased to the next level (9 mg, 14.5 mg or 17.2 mg once daily) after at least 30 days on the current dose, based on treatment response and tolerability. Maximum 17.2 mg once daily | Foundayo SmPC section 4.2. More than one tablet a day should not be taken to achieve the effect of a higher dose. The maximum is 9 mg once daily with a strong CYP3A4 inhibitor or a clinical OATP1B inhibitor, and strong CYP3A4 inducers should be avoided. Not recommended in severe hepatic impairment; no dose adjustment for age, sex, race or ethnicity, body weight, renal function including end-stage renal disease, or mild or moderate hepatic impairment. Safety and efficacy under 18 years have not been established. |
| Type 2 diabetes in adults (Foundayo, MHRA-licensed) | Oral, once daily | Same schedule as above: start 0.8 mg once daily, with increases after at least 30 days on each dose, to a maximum of 17.2 mg once daily | Foundayo SmPC sections 4.2 and 4.5. When added to existing therapy with a sulfonylurea and/or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered, and blood glucose self-monitoring is necessary to adjust it. When added to existing metformin and/or SGLT2 inhibitor therapy, the current dose of metformin and/or the SGLT2 inhibitor can be continued. |
| Administration and missed doses (both indications) | Oral; swallow the film-coated tablet whole | Once daily at any time of day, without food or water restriction. Tablets should not be broken, crushed or chewed. If a dose is missed, resume dosing as soon as possible; more than one tablet should not be taken per day | Foundayo SmPC section 4.2. The SmPC section 5.2 reports no clinically relevant food effect on exposure. |
| Clinical-trial capsule doses (not the licensed tablets) | Oral hard capsules used in the Phase 3 trials | Weight-management trials (ATTAIN-1, ATTAIN-2): 6, 12 and 36 mg capsules. Type 2 diabetes trials: ACHIEVE-1, -2 and -5, 3, 12 and 36 mg capsules; ACHIEVE-3, 12 and 36 mg capsules. | Foundayo SmPC section 5.1 states that the clinical studies were conducted with hard capsules and that tablets and capsules are not substitutable on a mg-per-mg basis. Equal-effect pairs (tablet to capsule): 0.8 to 1 mg, 2.5 to 3 mg, 5.5 to 6 mg, 9 to 12 mg, 14.5 to 24 mg and 17.2 to 36 mg. |
Reconstitution & storage
Summarised studies
| Year | Model | Outcome | Citation | Source |
|---|---|---|---|---|
| 2025 | Adults with obesity, without diabetes, Phase 3 RCT | Weight change -11.2% (36 mg capsule) versus -2.1% with placebo at 72 weeks (treatment-regimen estimand) | Wharton S, et al. N Engl J Med. 2025 Nov 6 | PMID 40960239 |
| 2025 | Adults with obesity or overweight and type 2 diabetes, Phase 3 RCT | Weight change -9.6% (36 mg capsule) versus -2.5% with placebo at 72 weeks (treatment-regimen estimand) | Horn DB, et al. Lancet. 2025 | PMID 41275875 |
| 2025 | Adults with early type 2 diabetes, Phase 3 RCT | HbA1c change -1.24/-1.47/-1.48 percentage points (3/12/36 mg capsules) versus -0.41 with placebo at 40 weeks | Rosenstock J, et al. N Engl J Med. 2025 Sep 18 | PMID 40544435 |
| 2026 | Adults with type 2 diabetes on metformin, open-label phase 3 RCT | HbA1c change -1.23/-1.50/-1.56% (3/12/36 mg capsules) versus -0.81% with dapagliflozin 10 mg at 40 weeks | Welch M, et al. Lancet. 2026 | PMID 42259339 |
| 2026 | Adults with type 2 diabetes on metformin, open-label head-to-head phase 3 RCT | HbA1c change -1.71% (12 mg) and -1.91% (36 mg) versus -1.23% (semaglutide 7 mg) and -1.47% (semaglutide 14 mg) at 52 weeks | Rosenstock J, et al. Lancet. 2026 Mar 21 | PMID 41765029 |
| 2026 | Adults with type 2 diabetes at increased cardiovascular risk, active-comparator phase 3 RCT | MACE-4 hazard ratio 0.84 (95% CI 0.59 to 1.20) versus insulin glargine; non-inferiority shown | Klein KR, et al. Lancet. 2026 Oct 17 | PMID 42815506 |
| 2026 | Adults with type 2 diabetes on insulin glargine, phase 3 RCT | HbA1c change -1.58/-1.88/-1.82% (3/12/36 mg capsules) versus -0.79% with placebo at 40 weeks | Giorgino F, et al. JAMA. 2026 Aug 4 | PMID 42251769 |
| 2026 | Adults previously treated with tirzepatide or semaglutide, phase 3b RCT | Weight reduction maintained: 74.7% and 79.3% with orforglipron versus 49.2% and 37.6% with placebo at 52 weeks | Aronne LJ, et al. Nat Med. 2026 | PMID 42120723 |
| 2026 | Pooled analysis of seven Phase 3 trials | No cases consistent with drug-induced liver injury or Hy's Law with orforglipron; hepatic adverse events balanced with comparators | Wharton S, et al. Diabetes Obes Metab. 2026 Sep | PMID 42338042 |
| 2023 | Adults with obesity or overweight, without diabetes, Phase 2 RCT | Weight change -9.4% to -14.7% with orforglipron versus -2.3% with placebo at 36 weeks | Wharton S, et al. N Engl J Med. 2023 Sep 7 | PMID 37351564 |
| 2023 | Adults with type 2 diabetes, Phase 2 RCT | HbA1c change up to -2.10% and body weight up to -10.1 kg at 26 weeks, versus -0.43% and -2.2 kg with placebo | Frias JP, et al. Lancet. 2023 Aug 5 | PMID 37369232 |
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1)
Wharton S, et al. N Engl J Med. 2025 Nov 6 · 2025 · PMID 40960239
Phase 3, multinational, double-blind trial of once-daily orforglipron 6, 12 or 36 mg versus placebo for 72 weeks in adults with obesity without diabetes (3127 randomised). On the treatment-regimen estimand, mean body-weight change was -7.5%, -8.4% and -11.2% with orforglipron versus -2.1% with placebo. In the 36 mg group, 54.6% had a reduction of 10% or more, 36.0% of 15% or more and 18.4% of 20% or more, versus 12.9%, 5.9% and 2.8% with placebo. Doses were capsules; the UK SmPC table reports different percentages (-7.8%, -9.3% and -12.4% versus -0.9%) from a different analysis.
PubMedOrforglipron for the treatment of obesity in people with type 2 diabetes (ATTAIN-2)
Horn DB, et al. Lancet. 2025 · 2025 · PMID 41275875
Phase 3, double-blind, placebo-controlled trial of orforglipron 6, 12 or 36 mg versus placebo for 72 weeks in adults with obesity or overweight and type 2 diabetes (1613 randomised). On the treatment-regimen estimand, mean body-weight change was -5.1%, -7.0% and -9.6% with orforglipron versus -2.5% with placebo. Treatment discontinuations due to adverse events were 6.1 to 9.9% with orforglipron versus 4.1% with placebo.
PubMedOrforglipron in early type 2 diabetes (ACHIEVE-1)
Rosenstock J, et al. N Engl J Med. 2025 Sep 18 · 2025 · PMID 40544435
Phase 3 trial of orforglipron 3, 12 or 36 mg versus placebo for 40 weeks in adults with early type 2 diabetes (559 randomised; mean baseline HbA1c 8.0%). Mean HbA1c change was -1.24, -1.47 and -1.48 percentage points with orforglipron versus -0.41 with placebo, and body-weight change was -4.5%, -5.8% and -7.6% versus -1.7%. No episodes of severe hypoglycaemia were reported.
PubMedOrforglipron compared with dapagliflozin in type 2 diabetes inadequately controlled with metformin (ACHIEVE-2)
Welch M, et al. Lancet. 2026 · 2026 · PMID 42259339
Open-label, non-inferiority phase 3 trial of orforglipron 3, 12 or 36 mg versus dapagliflozin 10 mg for 40 weeks (962 randomised). On the treatment-regimen estimand, HbA1c change was -1.23%, -1.50% and -1.56% with orforglipron versus -0.81% with dapagliflozin; all orforglipron doses were non-inferior. Gastrointestinal adverse events occurred in 46 to 54% of orforglipron groups versus 12% with dapagliflozin.
PubMedOrforglipron compared with oral semaglutide in type 2 diabetes (ACHIEVE-3)
Rosenstock J, et al. Lancet. 2026 Mar 21 · 2026 · PMID 41765029
Open-label phase 3 non-inferiority trial in adults with type 2 diabetes inadequately controlled with metformin (1698 randomised) for 52 weeks. On the treatment-regimen estimand from a baseline HbA1c of 8.3%, HbA1c change was -1.71% with orforglipron 12 mg and -1.91% with 36 mg, versus -1.23% with oral semaglutide 7 mg and -1.47% with 14 mg. Non-inferiority was met and both orforglipron doses showed superiority to both semaglutide doses. Gastrointestinal events, discontinuations due to adverse events and mean pulse-rate increase were higher with orforglipron.
PubMedCardiovascular safety of orforglipron versus insulin glargine (ACHIEVE-4)
Klein KR, et al. Lancet. 2026 Oct 17 · 2026 · PMID 42815506
Event-driven, open-label phase 3 non-inferiority trial in adults with type 2 diabetes at increased cardiovascular risk (2749 randomised; 85.9% had established cardiovascular disease). Over a median follow-up of 2 years the primary outcome (MACE-4) occurred in 57 (4.2%) of 1358 orforglipron participants and 67 (5.0%) of 1343 insulin glargine participants (hazard ratio 0.84; 95% CI 0.59 to 1.20), showing non-inferiority. Gastrointestinal adverse events occurred in 62.1% versus 14.2%; clinically significant or severe hypoglycaemia occurred in 6.8% versus 19.2%.
PubMedOrforglipron added to titrated insulin glargine in type 2 diabetes (ACHIEVE-5)
Giorgino F, et al. JAMA. 2026 Aug 4 · 2026 · PMID 42251769
Randomised, double-blind phase 3 study of orforglipron 3, 12 or 36 mg versus placebo for 40 weeks in adults with type 2 diabetes taking insulin glargine (546 randomised; mean baseline HbA1c 8.50%). HbA1c change was -1.58%, -1.88% and -1.82% with orforglipron versus -0.79% with placebo, and body-weight change was -2.6%, -4.8% and -5.4% versus 0.2%. Orforglipron did not increase the risk of clinically significant hypoglycaemia versus placebo.
PubMedOrforglipron for maintenance of body weight reduction (ATTAIN-MAINTAIN)
Aronne LJ, et al. Nat Med. 2026 · 2026 · PMID 42120723
Double-blind, placebo-controlled phase 3b trial in people previously treated with tirzepatide (cohort 1, n=205) or semaglutide (cohort 2, n=171) in SURMOUNT-5, randomised to orforglipron once daily or placebo. At week 52, participants who had reached a body-weight plateau maintained a model-based estimate of 74.7% (tirzepatide cohort) and 79.3% (semaglutide cohort) of their weight reduction with orforglipron, versus 49.2% and 37.6% with placebo. The authors note the absence of a comparator arm continuing injectable treatment and the 1-year duration.
PubMedHepatic safety of orforglipron: pooled analysis of the Phase 3 trials
Wharton S, et al. Diabetes Obes Metab. 2026 Sep · 2026 · PMID 42338042
Pooled analysis of seven Phase 3 trials (11,220 participants: 6,920 on orforglipron and 4,300 on pooled comparators) with follow-up of up to 104 weeks including safety follow-up. Orforglipron was associated with mean reductions in ALT and AST. Six participants on orforglipron and six on comparators had ALT or AST at least 3 times the upper limit of normal with bilirubin at least 2 times the upper limit; alternative causes accounted for all the orforglipron cases, which therefore did not meet criteria for drug-induced liver injury (Hy's Law). The authors concluded that orforglipron treatment was not associated with drug-induced liver injury.
PubMedDaily oral GLP-1 receptor agonist orforglipron for adults with obesity (Phase 2)
Wharton S, et al. N Engl J Med. 2023 Sep 7 · 2023 · PMID 37351564
Phase 2 trial of orforglipron 12, 24, 36 or 45 mg daily versus placebo for 36 weeks in 272 adults with obesity, or overweight plus a weight-related condition, without diabetes. At week 36 mean weight change ranged from -9.4% to -14.7% with orforglipron versus -2.3% with placebo; gastrointestinal events led to discontinuation in 10 to 17% of participants across dose cohorts.
PubMedEfficacy and safety of oral orforglipron in patients with type 2 diabetes (Phase 2)
Frias JP, et al. Lancet. 2023 Aug 5 · 2023 · PMID 37369232
Phase 2 dose-response trial in 383 adults with type 2 diabetes treated with diet and exercise with or without metformin. At week 26 mean HbA1c change with orforglipron was up to -2.10% (-1.67% placebo adjusted) versus -0.43% with placebo and -1.10% with dulaglutide, and mean body-weight change was up to -10.1 kg versus -2.2 kg with placebo.
PubMedSafety profile
This section summarises the UK SmPC for Foundayo on the emc (section 4.8 unless stated); the product carries a black triangle and is subject to additional monitoring. In placebo-controlled Phase 3 studies, 4158 patients were exposed to orforglipron alone or in combination with other glucose-lowering medicines. The most frequently reported adverse reactions were gastrointestinal and were mostly mild or moderate; the incidence of nausea, vomiting and diarrhoea was higher during dose escalation and decreased over time. The MHRA lists the most common side effects as nausea, constipation, diarrhoea, vomiting, dyspepsia and abdominal pain.
Gastrointestinal disorders. In the placebo-controlled weight-management Phase 3 studies, gastrointestinal disorders occurred in 60.1% (6 mg capsules), 67.4% (12 mg) and 68.7% (36 mg) of patients versus 36.3% with placebo, and discontinuation due to gastrointestinal adverse reactions occurred in 3.7%, 6.3% and 6.8% versus 0.6%. In the placebo-controlled type 2 diabetes studies the corresponding figures were 43.2% (3 mg), 57.6% (12 mg) and 59.1% (36 mg) versus 25.9%, with discontinuation in 2.1%, 4.1% and 6.2% versus 0.4%. The SmPC states that orforglipron has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and should be used with caution in them (section 4.4).
Pancreatitis. Acute pancreatitis has been reported in patients treated with orforglipron. Section 4.4 states that orforglipron has not been studied in patients with a history of pancreatitis and should be used with caution in them; if pancreatitis is suspected it should be discontinued, and if the diagnosis is confirmed it should not be restarted. In weight-management studies, mean percentage increases from baseline in amylase and lipase were 18.9% and 28.8% with orforglipron versus 2.9% and 3.8% with placebo; the SmPC states their clinical significance is unknown in the absence of other signs and symptoms of pancreatitis.
Other SmPC warnings (section 4.4) and adverse reactions (section 4.8). Gastrointestinal reactions may lead to dehydration and volume depletion, which could cause acute kidney injury. Hypotension may occur and was more frequent in patients on antihypertensive therapy. Acute gallbladder disease has been reported with GLP-1 receptor agonists including orforglipron; cholelithiasis was reported in 1.3% of patients on orforglipron versus 0.6% on placebo in weight-management studies. Orforglipron has not been studied in patients receiving or planning treatment for diabetic retinopathy or macular oedema, and rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Pulmonary aspiration has been reported with long-acting GLP-1 receptor agonists in patients undergoing general anaesthesia or deep sedation. There is no experience in NYHA class IV heart failure and it is not recommended in these patients. Hair loss was reported in 3.7% of patients on orforglipron versus 1.8% on placebo in weight-management studies. Post-marketing and class reports listed in section 4.8 include non-arteritic anterior ischaemic optic neuropathy with GLP-1 receptor agonist products, and anaphylaxis and angioedema.
Hypoglycaemia. Patients taking orforglipron with an insulin secretagogue (for example a sulfonylurea) or insulin may have an increased risk of hypoglycaemia, and a reduction in the dose of the sulfonylurea or insulin may be considered.
Heart rate. Mean pulse rate increased from baseline, generally peaking during dose escalation (6.7 to 8.6 beats per minute in weight-management studies and 4.7 to 7.6 in type 2 diabetes studies), and then gradually decreased; at week 72 in weight-management studies the mean change was 3.9 to 5.2 beats per minute. Tachycardia was reported in 2.7% of patients on orforglipron versus 0.8% on placebo in the weight-management studies.
Liver. The SmPC does not recommend orforglipron in severe hepatic impairment (section 4.2); in participants with severe hepatic impairment, exposure after a single 1 mg capsule dose was 4.63-fold higher than in participants with normal hepatic function (section 5.2). A pooled analysis of seven Phase 3 trials (11,220 participants, of whom 6,920 received orforglipron; Wharton et al., Diabetes Obes Metab 2026, PMID 42338042) found mean reductions in ALT and AST with orforglipron. Six participants on orforglipron and six on comparators had ALT or AST at least 3 times the upper limit of normal with bilirubin at least 2 times the upper limit; alternative causes accounted for all the orforglipron cases, and the authors concluded that orforglipron treatment was not associated with drug-induced liver injury.
Thyroid. The SmPC (section 5.3) states that orforglipron is not pharmacologically active in rats or mice and was non-carcinogenic in a 2-year rat study and a 26-week transgenic mouse study. For other GLP-1 receptor agonists that are active in rodents, thyroid C-cell hyperplasia and neoplasia have been observed and are considered a class effect; the relevance for humans is considered low but cannot be completely excluded. The UK SmPC section 4.3 lists hypersensitivity as the only contraindication. The US label (DailyMed) carries a boxed warning for the risk of thyroid C-cell tumours and contraindicates use in people with a personal or family history of medullary thyroid carcinoma or MEN 2.
Trial safety context. In ACHIEVE-3, gastrointestinal events, discontinuations due to adverse events and the mean increase in pulse rate were higher with orforglipron than with oral semaglutide (PMID 41765029). In ACHIEVE-4, gastrointestinal adverse events were reported in 62.1% of orforglipron participants versus 14.2% on insulin glargine, and clinically significant or severe hypoglycaemia in 6.8% versus 19.2% (PMID 42815506). Suspected side effects can be reported to the MHRA Yellow Card scheme.
Reported contraindications & cautions
- Hypersensitivity to the active substance or to any of the excipients (the only contraindication listed in UK SmPC section 4.3)
- Pregnancy: should not be used during pregnancy; discontinue at least 3 weeks before a planned pregnancy because of the half-life, and women of childbearing potential should use effective contraception (SmPC section 4.6; a caution rather than a section 4.3 contraindication)
- Breast-feeding: the SmPC (section 4.6) states that orforglipron should not be used during breast-feeding; it is not listed in section 4.3
- Severe hepatic impairment: not recommended (SmPC sections 4.2 and 5.2)
- History of pancreatitis: not studied, use with caution; if pancreatitis is confirmed, orforglipron should not be restarted (SmPC section 4.4)
- Severe gastrointestinal disease, including severe gastroparesis: not studied, use with caution (SmPC section 4.4)
- Dehydration from gastrointestinal effects may lead to acute kidney injury (SmPC section 4.4)
- Hypotension: may occur and was more frequent with concomitant antihypertensive therapy (SmPC section 4.4)
- Diabetic retinopathy: not studied in patients receiving or planning treatment for retinopathy or macular oedema; rapid improvement in glucose control has been associated with a temporary worsening (SmPC section 4.4)
- General anaesthesia or deep sedation: pulmonary aspiration has been reported with long-acting GLP-1 receptor agonists (SmPC section 4.4)
- NYHA class IV heart failure: no experience, not recommended (SmPC section 4.4)
- Medullary thyroid carcinoma or MEN 2: a contraindication and boxed warning in the US label, but not a contraindication in the UK SmPC (section 4.3 lists hypersensitivity only); discuss any personal or family history with the prescriber
- Concomitant use with another GLP-1 receptor agonist: the US label states this is not recommended (limitation of use); it is not a contraindication in UK SmPC section 4.3, which lists hypersensitivity only
Known interactions (product label)
- Strong CYP3A4 inhibitors: clarithromycin increased orforglipron AUC 3.5-fold and Cmax 1.9-fold; the maximum dose is the 9 mg tablet once daily with a strong CYP3A4 inhibitor (for example ketoconazole, clarithromycin, itraconazole). Strong CYP3A4 inhibitors that also inhibit OATP1B (for example ritonavir, telaprevir) should be avoided (SmPC sections 4.2 and 4.5).
- OATP1B inhibitors: cyclosporine increased orforglipron AUC 2.6-fold and Cmax 1.3-fold; the maximum dose is 9 mg once daily with a clinical OATP1B inhibitor (SmPC sections 4.2 and 4.5).
- CYP3A4 inducers: carbamazepine decreased orforglipron AUC by 82% and Cmax by 55%. Strong inducers (for example rifampicin, phenytoin, St John's wort) should be avoided, and effectiveness should be monitored with moderate inducers (SmPC section 4.5).
- Oral hormonal contraceptives: orforglipron may reduce their efficacy; switch to a non-oral method or add a barrier method for 30 days after starting orforglipron and for 30 days after each dose escalation (SmPC section 4.5).
- Simvastatin: exposure to the active metabolite simvastatin acid was increased up to 2.5-fold, and the SmPC states the simvastatin dose should be halved. Rosuvastatin: caution when the rosuvastatin dose exceeds 20 mg. Oral topotecan: monitor for adverse reactions (SmPC section 4.5).
- Delayed gastric emptying: when paracetamol and orforglipron were co-administered, paracetamol Cmax decreased by 28%; the SmPC states that no clinically relevant effect on commonly administered medicines is expected based on modelling (section 4.5).
- Sulfonylureas and insulin: increased hypoglycaemia risk; a reduction in the dose of the sulfonylurea or insulin may be considered. Metformin and SGLT2 inhibitors can be continued unchanged (SmPC sections 4.2, 4.4 and 4.5).
- Interaction studies were conducted with the hard capsule form (SmPC section 4.5).
UK regulatory status
Orforglipron is licensed in the United Kingdom as Foundayo, a prescription only medicine. The MHRA announced on 10 August 2026 that it had authorised orforglipron (Foundayo), and the UK SmPC gives 10 August 2026 as the date of first authorisation (section 9). The marketing authorisation holder is Eli Lilly Nederland B.V. The emc lists Foundayo film-coated tablets as six separate products, one per strength (0.8 mg, product 102527, PL 14895/0369; 2.5 mg, 102528, PL 14895/0370; 5.5 mg, 102529, PL 14895/0371; 9 mg, 102530, PL 14895/0372; 14.5 mg, 102531, PL 14895/0373; 17.2 mg, 102532, PL 14895/0374), with the same SmPC text apart from strength and licence number. The emc page was last updated on 14 August 2026, and the product is subject to additional monitoring (black triangle).
Section 4.1 of the SmPC lists two indications: (1) as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial BMI of 30 kg/m2 or more (obesity), or 27 kg/m2 to under 30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity, for example prediabetes or type 2 diabetes mellitus, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease; and (2) treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise, as monotherapy or in combination with other medicinal products for the treatment of diabetes. The SmPC states that the safety and efficacy of orforglipron in children aged less than 18 years have not been established (section 4.2).
NHS availability. The gov.uk announcement states that the tablet is not currently available via the NHS, and that decisions on NHS use will follow established processes, including an evaluation by the National Institute for Health and Care Excellence (NICE). This page does not summarise any NICE guidance on orforglipron; check NICE for the current position.
Supply. The MHRA states that all GLP-1 medicines are prescription only medicines, which means they can only be obtained from a registered pharmacy with a prescription from a doctor, and that buying GLP-1 medicines from unregulated sellers carries serious health risks. Orforglipron sold as a research chemical is not the licensed product.
Outside the UK. The US FDA approved Foundayo on 1 April 2026 (NDA 220934) for adults with obesity, or overweight with at least one weight-related comorbid condition; the US label has no type 2 diabetes indication, and Lilly's second-quarter 2026 results list a US type 2 diabetes submission under regulatory progress. In the EU, the CHMP adopted a positive opinion on 15 October 2026 recommending a marketing authorisation for type 2 diabetes and weight management; a European Commission decision had not been confirmed when this page was last updated, so orforglipron should not be described as approved in the EU.
Orforglipron is not named on the WADA Prohibited List; athletes should check the current List with their anti-doping organisation.
Frequently asked questions
What is orforglipron?
Is orforglipron licensed in the UK, and is it a prescription-only medicine?
Is orforglipron available on the NHS?
What are the licensed doses and how is it taken?
How much weight did people lose in the trials?
How does orforglipron compare with oral semaglutide?
What are the safety concerns with orforglipron?
What is the thyroid cancer warning?
Does orforglipron affect the contraceptive pill?
Is orforglipron approved in the US and EU?
Is orforglipron a peptide?
Is orforglipron prohibited in sport?
References
- Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). Wharton S, et al. N Engl J Med. 2025 Nov 6 (2025). PMID 40960239
- Orforglipron for the treatment of obesity in people with type 2 diabetes (ATTAIN-2). Horn DB, et al. Lancet. 2025 (2025). PMID 41275875
- Orforglipron in early type 2 diabetes (ACHIEVE-1). Rosenstock J, et al. N Engl J Med. 2025 Sep 18 (2025). PMID 40544435
- Orforglipron compared with dapagliflozin in type 2 diabetes inadequately controlled with metformin (ACHIEVE-2). Welch M, et al. Lancet. 2026 (2026). PMID 42259339
- Orforglipron compared with oral semaglutide in type 2 diabetes (ACHIEVE-3). Rosenstock J, et al. Lancet. 2026 Mar 21 (2026). PMID 41765029
- Cardiovascular safety of orforglipron versus insulin glargine (ACHIEVE-4). Klein KR, et al. Lancet. 2026 Oct 17 (2026). PMID 42815506
- Orforglipron added to titrated insulin glargine in type 2 diabetes (ACHIEVE-5). Giorgino F, et al. JAMA. 2026 Aug 4 (2026). PMID 42251769
- Orforglipron for maintenance of body weight reduction (ATTAIN-MAINTAIN). Aronne LJ, et al. Nat Med. 2026 (2026). PMID 42120723
- Hepatic safety of orforglipron: pooled analysis of the Phase 3 trials. Wharton S, et al. Diabetes Obes Metab. 2026 Sep (2026). PMID 42338042
- Daily oral GLP-1 receptor agonist orforglipron for adults with obesity (Phase 2). Wharton S, et al. N Engl J Med. 2023 Sep 7 (2023). PMID 37351564
- Efficacy and safety of oral orforglipron in patients with type 2 diabetes (Phase 2). Frias JP, et al. Lancet. 2023 Aug 5 (2023). PMID 37369232
- UK SmPC: Foundayo 0.8 mg film-coated tablets on the emc (product 102527; strengths 2.5 to 17.2 mg are emc products 102528 to 102532)
- MHRA — UK first in Europe to authorise orforglipron for weight management and type 2 diabetes (10 August 2026)
- DailyMed — Foundayo (orforglipron) US prescribing information
- openFDA Drugs@FDA record — NDA 220934 (Foundayo, original approval 1 April 2026)
- FDA — Novel Drug Approvals for 2026
- EMA — Foundayo (CHMP positive opinion, 15 October 2026)
- Eli Lilly — FDA approves Foundayo (1 April 2026)
- Eli Lilly — second-quarter 2026 financial results
- PubChem — orforglipron (CID 137319706)
- Wharton et al. 2025 — ATTAIN-1 (PMID 40960239)
- Horn et al. 2025 — ATTAIN-2 (PMID 41275875)
- Rosenstock et al. 2025 — ACHIEVE-1 (PMID 40544435)
- Welch et al. 2026 — ACHIEVE-2 (PMID 42259339)
- Rosenstock et al. 2026 — ACHIEVE-3 (PMID 41765029)
- Klein et al. 2026 — ACHIEVE-4 (PMID 42815506)
- Giorgino et al. 2026 — ACHIEVE-5 (PMID 42251769)
- Aronne et al. 2026 — ATTAIN-MAINTAIN (PMID 42120723)
- Wharton et al. 2026 — pooled hepatic safety analysis (PMID 42338042)
- Wharton et al. 2023 — Phase 2 obesity (PMID 37351564)
- Frias et al. 2023 — Phase 2 type 2 diabetes (PMID 37369232)
Related peptides
Semaglutide
A long-acting GLP-1 receptor agonist developed by Novo Nordisk, modified from native GLP-1 with aminoisobutyric acid (Aib) at position 8 (DPP-4 resistance) and a C18 fatty diacid moiety on lysine 26 (albumin binding for ~1-week half-life). Licensed in the UK by the MHRA for type-2 diabetes (Ozempic, subcutaneous; Rybelsus, oral) and chronic weight management (Wegovy, subcutaneous injection and oral tablets). The most clinically significant GLP-1 receptor agonist of the late 2020s.
Tirzepatide
A dual GIP and GLP-1 receptor agonist: an amino acid sequence with a C20 fatty diacid moiety that enables albumin binding, giving an elimination half-life of approximately 5 days and once-weekly subcutaneous dosing. Licensed in the UK as Mounjaro (KwikPen), a prescription only medicine for type 2 diabetes in adults, adolescents and children aged 10 years and above and for weight management in adults (Zepbound is the US brand only). In the head-to-head SURPASS-2 and SURMOUNT-5 trials tirzepatide produced greater HbA1c reduction and weight loss than semaglutide.
Retatrutide
An Eli Lilly triple agonist of the GLP-1, GIP, and glucagon receptors — an extension of tirzepatide's dual-agonist mechanism with added glucagon-receptor activation. Phase II results (Jastreboff et al., NEJM 2023) showed 24.2% mean body weight loss over 48 weeks at the 12 mg dose, and the Phase III TRIUMPH-1 trial (Jastreboff et al., NEJM 2026) reported 25.0% at 12 mg over 80 weeks versus 3.9% with placebo. Not approved in any jurisdiction as of 29 October 2026; Eli Lilly has said it plans to submit a Biologics License Application to the US FDA in the first quarter of 2027.
CagriSema (cagrilintide + semaglutide)
A Novo Nordisk fixed-dose combination of semaglutide (the licensed GLP-1 receptor agonist) with cagrilintide (a long-acting amylin analogue) — pairing two appetite-suppressing mechanisms in a single weekly subcutaneous injection. Novo Nordisk submitted a New Drug Application to the US FDA on 18 December 2025 for weight management, and the pivotal REDEFINE 1 and 2 trials were published in NEJM in 2025. In REDEFINE 4, an open-label comparison with tirzepatide 15 mg, Novo Nordisk reported that CagriSema did not meet the primary endpoint of non-inferiority. Not approved in the UK, EU or US as of 29 October 2026.
Survodutide
A Boehringer Ingelheim dual GLP-1/glucagon receptor agonist, licensed from Zealand Pharma — a two-receptor mechanism intermediate between semaglutide's single GLP-1R agonism and retatrutide's triple GLP-1R/GIPR/glucagon-R agonism. The GLP-1 + glucagon combination pairs appetite suppression (GLP-1R) with proposed energy-expenditure enhancement (glucagon-R) without the additional GIPR dimension of retatrutide. The Phase III SYNCHRONIZE-1, SYNCHRONIZE-2 and SYNCHRONIZE-MASLD trials were published in 2026; survodutide remains investigational and is not approved in any jurisdiction (Zealand Pharma company announcement, 1 October 2026).